ASH 2022 Conference Coverage
Playback speed
10 seconds
ASH 2022 Efficacy & Safety of Ruxolitinib for Treatment of Symptomatic CMML: Results of a Multicenter Phase II Clinical Trial
By
ASH 2022 Conference Coverage
FEATURING
Eric Padron
By
ASH 2022 Conference Coverage
FEATURING
Eric Padron
41 views
December 19, 2022
Login to view comments.
Click here to Login
Leukemia